ArticlePediatric rheumatology online journal2026
An interferonopathy associated with a monoallelic variant in TRIM28.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this work, we describe the clinical and functional changes in a family with a novel type I interferonopathy phenotype which we suggest could be associated with a TRIM28 variant, presenting with chilblains, skin ulceration, lipodystrophy and calcinosis. TRIM28 has multiple roles in regulating human health and disease, which include DNA repair and anti-viral response. The latter includes negative regulation of IRF7, one of the master regulators of the interferon response.
methodsWhole exome sequencing and targeted panel sequencing was performed on DNA extracted from peripheral blood. Functional work included gene (qPCR), protein (WB) and cytokine (MSD and SIMOA) expression studies. Transfection studies of siRNA in control Human Dermal Fibroblast Cells (HDFCs) using RNAiMAX and of wild-type protein in patient HDFCs using FuGENE HD were also performed.
resultsAnalysis of WES data according to a dominant model with incomplete penetrance revealed TRIM28 c.A623G; p.Y208C in the proband of Family A and his mildly affected mother. Gene expression studies revealed persistent elevation of interferon inducible proteins including increased gene as well as protein expression of IRF7. Cytokine measurements revealed a marked elevation of pro-inflammatory cytokines particularly IFNβ in affected individuals. A good clinical and functional response to treatment with baricitinib was documented, however the proband subsequently died of septic complications. TRIM28-siRNA transfection into control HDFCs resulted in changes in gene, protein and cytokine expression similar to those seen in the proband. Transfection of a wild-type pEGFP-TRIM28 plasmid into the proband's HDFCs achieved partial rescue of the cellular phenotype. DISCUSSION: We describe a novel and severe interferonopathy potentially associated with an autosomal dominant TRIM28 variant with an incomplete penetrance disease model, presenting with skin ulceration, calcinosis, high interferon scores, and upregulation of IRF7. Pathogenicity was supported by TRIM28 gene silencing in healthy HDFCs. Polymorphisms in other genes such as ITGAM could modulate penetrance and expressivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.